PROCTOCORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROCTOCORT (PROCTOCORT).
PROCTOCORT (hydrocortisone acetate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Hydrocortisone acetate is metabolized primarily in the liver via reduction and conjugation, forming inactive metabolites that are excreted renally. Topical use minimizes systemic absorption, thus hepatic metabolism is limited. |
| Excretion | Primarily hepatic metabolism; renal excretion of metabolites accounts for ~60-70%, with ~15-25% excreted in feces via biliary elimination. Unchanged drug in urine is negligible (<1%). |
| Half-life | Terminal elimination half-life is approximately 3.5 hours (range 2-5 hours) for triamcinolone acetonide. Clinical context: short half-life supports BID or TID dosing in topical and rectal administration. |
| Protein binding | Approximately 75-80% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Volume of distribution is approximately 1.4 L/kg (range 1.2-1.7 L/kg). This reflects moderate tissue penetration and distribution into interstitial fluid. |
| Bioavailability | Rectal administration: systemic bioavailability is variable, estimated at 10-30% due to extensive first-pass metabolism in the liver. Topical application: minimal systemic absorption (<1% on intact skin; up to 5% on inflamed or damaged mucosa). |
| Onset of Action | Topical/rectal: clinical relief of inflammation and pruritus typically within 1-3 hours after application; maximum effect may require 1-3 days of regular use. |
| Duration of Action | Duration of anti-inflammatory effect is approximately 8-12 hours after single application. Clinical note: sustained symptom relief with BID dosing; resolution of acute hemorrhoidal symptoms may take 3-7 days. |
| Molecular Weight | 404.49 Da (hydrocortisone acetate) |
Rectal: One 30 mg suppository twice daily (morning and evening) for 2-3 weeks, then taper down as needed. Alternatively, 1% cream or ointment applied rectally 3-4 times daily.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment due to potential corticosteroid accumulation. |
| Pediatric use | Safety and efficacy not established. Avoid use in children under 2 years. For older children, use lowest effective dose under medical supervision (e.g., 1% cream applied sparingly once or twice daily). |
| Geriatric use | Use lowest effective dose; monitor for increased systemic absorption (skin thinning, adrenal suppression) with prolonged use. |
| 1st trimester | Hydrocortisone acetate (topical) is generally considered safe in pregnancy at low potency and limited use. However, systemic absorption is minimal with short-term topical application. No adequate well-controlled studies in pregnant women; use only if clearly needed. Avoid large areas, prolonged use, or occlusive dressings. |
| 2nd trimester | Same as t1. Topical corticosteroids are considered relatively safe with prudent use. Avoid high-potency or prolonged therapy. No known teratogenicity. |
| 3rd trimester | Topical corticosteroids are generally safe but avoid prolonged use near term due to potential for fetal adrenal suppression. No reports of congenital malformations. |
Clinical note
Comprehensive clinical and safety monograph for PROCTOCORT (PROCTOCORT).
| Placental transfer | Limited data; topical corticosteroids minimally absorbed systemically, so negligible placental transfer expected with proper use. Systemic corticosteroids cross placenta; hydrocortisone is inactivated by placental 11β-HSD2 but some active drug may reach fetus if maternal levels are high. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to hydrocortisone acetate or any componentUntreated bacterial, fungal, viral, or parasitic infections at application sitePerianal tuberculosis or syphilisProlonged use on large areas or under occlusive dressings without medical supervision
| Precautions | Prolonged use may lead to skin atrophy, striae, or secondary infection., Systemic absorption can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with occlusive dressings or use on large body areas., Avoid use in the presence of fungal or bacterial infections unless appropriately treated., Not for ophthalmic use. |
| Food/Dietary | No clinically significant food interactions. Avoid spicy or acidic foods if they exacerbate anorectal symptoms, but no specific dietary restrictions are required with Proctocort use. |
Loading safety data…
| Breastfeeding |
| Topical hydrocortisone acetate is considered compatible with breastfeeding when used short-term over small areas. Minimal systemic absorption. Avoid application to breast area to prevent infant ingestion. No known adverse effects in infants. |
| Lactation Rating | L2 (Possibly Compatible) |
| Teratogenic Risk | PROCTOCORT (hydrocortisone acetate) is a topical corticosteroid. Systemic absorption is minimal with topical use, but first trimester use should be avoided unless clearly needed. Animal studies have shown corticosteroids to be teratogenic, but no adequate human data. Second and third trimester use is generally considered low risk, though chronic high-dose exposure may cause intrauterine growth restriction and adrenal suppression in the neonate. |
| Fetal Monitoring | No specific maternal-fetal monitoring required for short-term topical use. If used extensively, prolonged, or on large areas, monitor for maternal adrenal suppression and fetal growth via ultrasound. |
| Fertility Effects | No known adverse effects on fertility with topical hydrocortisone. |
| Clinical Pearls | Proctocort (hydrocortisone) is a topical corticosteroid used for hemorrhoids and inflammatory anorectal conditions. Limit use to 5-7 days; prolonged use can cause skin atrophy, perianal dermatitis, or systemic absorption. Avoid in patients with perianal fungal or bacterial infections unless treating concomitant inflammation. Apply sparingly after bowel movements for optimal efficacy. |
| Patient Advice | Apply a small amount to the affected area after each bowel movement and at bedtime, but not more than 4 times daily. · Do not use for more than 5-7 days unless directed by a healthcare provider. · Avoid contact with eyes; if contact occurs, rinse thoroughly with water. · Inform your doctor if symptoms worsen or do not improve after 7 days. · Do not use if you have a fungal or bacterial infection in the area unless prescribed. · Keep the applicator clean and do not share with others to prevent infection. |